Samples*
|
Method
|
RIF
|
INH
|
EMB
|
PYR
|
STR
|
ETH
|
AMK
|
CAP
|
FLQ
|
PAS
|
---|
por5
|
DST
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
S
|
S
|
|
TBProfiler
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
S
|
S
|
|
Mykrobe**
|
R
|
R
|
R
|
82%R
|
R
|
–
|
S
|
S
|
S
|
–
|
por6
|
DST
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
|
TBProfiler
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
|
Mykrobe
|
R
|
R
|
R
|
R
|
R
|
–
|
82%R
|
82%R
|
R
|
–
|
por7
|
DST
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
|
TBProfiler
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
R
|
S
|
|
Mykrobe
|
R
|
92%R
|
S
|
R
|
83%R
|
–
|
S
|
S
|
91%R
|
–
|
- DST drug susceptibility testing (R resistant, S sensitive); this table shows the percentage of replicates producing the correct result; − cannot be determined; bolded values indicate the % of replicates with DST phenotypes, where resistance mutations are not found in all replicates. Underlined values indicate where the variant is not present in software mutation library; RIF rifampicin, INH isoniazid, EMB ethambutol, PYR pyrazinamide, STR streptomycin, ETH ethionamide, AMK amikacin, CAP capreomycin, FLQ fluoroquinolones, PAS para-aminosalicylic acid. *All LAM4 strain-types or sub-lineage 4.3.4.2. **Mykrobe-Profiler TB (https://github.com/iqbal-lab/Mykrobe-predictor) implemented using its command-line version